- Home
- DVAX vs DMAC Comparison
DVAX vs DMAC Comparison
Compare DVAX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- DMAC
- Stock Information
- Founded
- DVAX 1996
- DMAC 2000
- Country
- DVAX United States
- DMAC United States
- Employees
- DVAX N/A
- DMAC N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- DVAX Health Care
- DMAC Health Care
- Exchange
- DVAX Nasdaq
- DMAC Nasdaq
- Market Cap
- DVAX 1.3B
- DMAC 310.1M
- IPO Year
- DVAX 2004
- DMAC N/A
- Fundamental
- Price
- DVAX $9.57
- DMAC $6.87
- Analyst Decision
- DVAX Buy
- DMAC Strong Buy
- Analyst Count
- DVAX 4
- DMAC 3
- Target Price
- DVAX $26.50
- DMAC $12.33
- AVG Volume (30 Days)
- DVAX 2.0M
- DMAC 448.5K
- Earning Date
- DVAX 11-06-2025
- DMAC 11-12-2025
- Dividend Yield
- DVAX N/A
- DMAC N/A
- EPS Growth
- DVAX N/A
- DMAC N/A
- EPS
- DVAX N/A
- DMAC N/A
- Revenue
- DVAX $316,268,000.00
- DMAC N/A
- Revenue This Year
- DVAX $23.23
- DMAC N/A
- Revenue Next Year
- DVAX $16.57
- DMAC N/A
- P/E Ratio
- DVAX N/A
- DMAC N/A
- Revenue Growth
- DVAX 26.66
- DMAC N/A
- 52 Week Low
- DVAX $9.20
- DMAC $3.19
- 52 Week High
- DVAX $14.63
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- DVAX 39.47
- DMAC 63.84
- Support Level
- DVAX $9.20
- DMAC $6.83
- Resistance Level
- DVAX $9.94
- DMAC $7.41
- Average True Range (ATR)
- DVAX 0.30
- DMAC 0.43
- MACD
- DVAX -0.04
- DMAC 0.03
- Stochastic Oscillator
- DVAX 31.90
- DMAC 73.62
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.